{
  "source": "PA-Notification-Scemblix.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1374-4\nProgram Prior Authorization/Notification\nMedication Scemblix® (asciminib)\nP&T Approval Date 12/2021, 12/2022, 12/2023, 12/2024\nEffective Date 3/1/2025\n1. Background:\nScemblix (asciminib) is a kinase inhibitor indicated for the treatment of adult patients with\nnewly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in\nchronic phase (CP), previously treated, or with a T315I mutation.\nThe National Comprehensive Cancer Network (NCCN) recommends the use of Scemblix for\ntreatment in myeloid/lymphoid neoplasms with eosinophilia and ABL1 rearrangement in chronic\nphase or blast phase and in CML for accelerated phase as primary treatment.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Scemblix will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+CML)\n1. Initial Authorization\na. Scemblix will be approved based on all the following criteria:\n(1) Diagnosis of chronic myeloid leukemia (CML)\n- AND –\n(2) Disease is Philadelphia chromosome (Ph+) or BCR:ABL1-positive\n© 2024 UnitedHealthcare Services, Inc.\n1\n- AND -\n(3) One of the following:\n(a) Used in newly diagnosed chronic phase CML (CP-CML)\n- OR -\n(b) Used in previously treated chronic phase CML (CP-CML)\n- OR -\n(c) Used in chronic phase CML (CP-CML) positive for a T315I mutation\n- OR",
    "(a) Used in newly diagnosed chronic phase CML (CP-CML)\n- OR -\n(b) Used in previously treated chronic phase CML (CP-CML)\n- OR -\n(c) Used in chronic phase CML (CP-CML) positive for a T315I mutation\n- OR -\n(d) Used in accelerated phase CML as primary treatment as a single agent\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Scemblix will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Scemblix\ntherapy\nAuthorization will be issued for 12 months.\nC. Myeloid/Lymphoid Neoplasms with Eosinophilia and ABL1 Gene Rearrangement\n1. Initial Authorization\na. Scemblix will be approved based on both of the following criteria:\n(1) Diagnosis of myeloid/lymphoid neoplasm with eosinophilia and ABL1\nrearrangement\n- AND -\n(2) Disease is in chronic or blast phase\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Scemblix will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Scemblix\ntherapy\n© 2024 UnitedHealthcare Services, Inc.\n2\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits and/or step therapy may be in place.\n4. Referenc",
    "osis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits and/or step therapy may be in place.\n4. References:\n1. Scemblix [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals\nCorporation. October 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed on\nOctober 24, 2024.\nProgram Prior Authorization/Notification – Scemblix (asciminib)\nChange Control\n12/2021 New program.\n12/2022 Annual review. Added state mandate and updated references.\n12/2023 Annual review. Added criteria for Myeloid/Lymphoid Neoplasms with\nEosinophilia and ABL1 Gene Rearrangement. Updated references.\n12/2024 Annual review. Updated CML criteria per NCCN guidelines and new\nexpanded indication. Updated background and references.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}